NHWK News and Press, NightHawk Biosciences Inc. From 04/03/23

2023-04-03 00:29:08 ET NightHawk Biosciences press release ( NYSE: NHWK ): FY GAAP EPS of -$1.70. Revenue of $6.4M (+204.8% Y/Y). As of December 31, 2022, the company had approximately $44.3M in cash, cash equivalents, and short-term investments. For further deta...

DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) , a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for th...

NightHawk Biosciences press release ( NYSE: NHWK ): Q3 GAAP EPS of -$0.51 misses by $0.16 . Revenue of $6M (vs. $0.5M Y/Y) beats by $5.03M . As of September 30, 2022, the company had approximately $57.4M in cash and cash equivalents, and short-term investments....

DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) , a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates f...

DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) , a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that its Scorpion subsidiary plans to host the gra...

DURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) , a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the construction of an advanced biosafety leve...

Nighthawk Biosciences ( NYSE: NHWK ) is up 21% in premarket trading after stating in an SEC filing it has entered into an R&D agreement with Lytic Solutions to develop a monkeypox vaccine. The company said that the Lytic' platform that will be used to generate monk...

NightHawk Biosciences press release ( NYSE: NHWK ): Q2 GAAP EPS of -$0.40 misses by $0.10 . Revenue of $0.05M (-89.1% Y/Y) misses by $1.1M . As of June 30, 2022, the Company had approximately $69.9 million in cash and cash equivalents. For further details...

DURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) , a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates f...

DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) , a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Stephan Kutzer, Ph.D. as Interi...